

FOI 23/932

Dear

Thank you for your FOI request dated 29th November where you requested information relating to the listing of an interaction between Fondaparinux Subcutaneous injections and Rivaroxaban tablets in the BNF and Stockley's interaction checker.

We can confirm that the MHRA is not the responsible body for these publications therefore the information you have requested is not held by the MHRA.

However, please note that the SPCs for all the DOACs have a section 4.3 entry outlining a relative contra-indication for the use of fondaparinux except under specific circumstances of switching anticoagulant therapy. This is cross-referenced in a section 4.5 entry for all DOACs.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Kind regards,

FOI Team

Safety & Surveillance Group

Medicines and Healthcare Products Regulatory Agency

10 South Colonnade, Canary Wharf, London E14 4PU